Stay updated with breaking news from Enteric Hyperoxaluria. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Synlogic, Inc. (NASDAQ: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced...
Joint Team from MIT and Synlogic Named a Biotechnology Grand Challenge Winner by Air Force Research Laboratory - Synlogic to provide bioprocess and manufacturing in joint effort to engineer novel investigational medicines to address battle fatigue - News provided by Share this article Share this article CAMBRIDGE, Mass., Feb. 2, 2021 /PRNewswire/ -- A collaboration between MIT Voigt Lab and Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, has been recognized by the Air Force Research Laboratory (AFRL) as a Biotechn...
Acorda Rises On Restructuring, ALXN Pauses COVID-19 Trial, SYBX On Watch Read on. 1. Acorda Rises on Corporate Restructuring Shares of Acorda Therapeutics Inc. (ACOR) jumped over 44% on Wednesday, on news of the company agreeing to sell its INBRIJA manufacturing operations in Chelsea, Massachusetts to Catalent, Inc. (CTLT) for $80 million in cash. INBRIJA is a prescription medicine from Acorda Therapeutics indicated for use when needed with hypomobility or OFF episodes in adults with Parkinson's disease treated with regular carbidopa/levodopa medicine. The companies have also inked a long-ter...
Synlogic Outlines Upcoming Clinical Milestones - Clinical proof of concept data in 2021 anticipated across multiple programs - News provided by Share this article CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ -- Synlogic, Inc. ( Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today outlined significant clinical milestones for 2021 and provided an overview of recent progress. "With three programs in clinical trials, multiple proof of concept opportunities, and a preclinical portfolio advancing rapidly towards the clinic, Synlogic i...